A systematic review of cost-effectiveness analyses across the acute kidney injury landscape.

A systematic review of cost-effectiveness analyses across the acute kidney injury landscape. Expert Rev Pharmacoecon Outcomes Res. 2021 Jan 31;: Authors: Suh K, Kellum JA, Kane-Gill SL Abstract INTRODUCTION: Acute kidney injury (AKI) is a complex and common condition associated with increased morbidity, mortality, and costs. Evidence from cost-effectiveness analysis (CEA) have targeted various aspects of AKI including detection with biomarkers, treatment with renal replacement therapy, and prevention when using contrast media. However, there has not been a systematic review of these studies across the entirety of AKI. Areas covered: PubMed, Embase, and Cochrane library were used to identify CEA studies that involved AKI from 2004 onwards. These studies compared AKI treatment through renal replacement therapies (n=6), prevention of contrast-induced-AKI (CI-AKI) using different media (n=3), and diagnosis with novel biomarkers (n=2). Treatment strategies for AKI focused on continuous versus intermittent renal replacement therapy. While there was no consensus, the majority of studies favored the continuous form. For contrast media, both studies found iodixanol to be cost-effective compared to iohexol for preventing CI-AKI. Additionally, novel biomarkers showed potential to be cost-effective in risk assessment and detection of AKI. Expert Opinion: Consistent criteria such as a lifetime time horizon would allow for better model comparisons...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research